WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals
World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

ISSN 2457-0400

Impact Factor  :  5.464

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • WJAHR New Impact Factor

    Its our Pleasure to Inform you that WJAHR Impact Factor has been increased from  4.897 to 5.464 due to high quality Publication at International Level

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR 1 March 2021 Issue has been Published, Kindly check it on http://www.wjahr.com/home/current_issues

  • WJAHR MARCH ISSUE PUBLISHED

    MARCH 2021 Issue has been successfully launched on 1 March 2021.

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

THE EFFECT OF ANTI TUBERCULOSIS DRUGS ON LIVER ENZYMES MOSUL IRAQ 2019-2020

Dr. Muyser Y. Alnaser*, Dr. Faris A. Mohammad

ABSTRACT

Background: Tuberculosis (TB) is a major cause of illness and death worldwide especially in Asia and Africa Anti tuberculosis drugs cause hepatotoxicity in some individuals leading to acute liver failure, which results in death. Such phenomena limit the clinical use of drugs, contributing to treatment failure that possibly causes drug resistance. Furthermore, associated risk factors for the development of anti- tuberculosis drug induced hepatotoxicity (anti-TB-DIH) so we need liver function test. Aim: Assess the percentage of liver dysfunction .change in liver enzymes in patients with active Mycobacterium Tuberculosis before and during treatment, and the implications of this for treatment completion in Mosul Governorate from (?/??/???? -?/?/????). Methodology: A total of ?? consecutive TB patients were prospectively followed up both clinically and biochemically before and during their course of anti-TB therapy with daily doses of rifampin, isoniazid. ethambutol, pyrazinamide, and streptomycin, Total serum Bilirubin (T.S.B). Serum Alanine Transaminase(ALT), Serum Aspartame Transaminase (S.G.O.T) were done for them. Result: ?? patients (?? male,?? female),all patients had subclinical mild-moderate increased in liver enzymes ,one patient the (T.S.B.)had reached more than double upper normal level, while in ? patients the (A.L.T),and ?patients the (A.S.T.) had reached more than upper normal level, one patient had (TB DILI) we stopped give him ( R ,PZ) because more than double upper normal level of (T.S.B), (A.LT.)and (A.S.T.). Conclusion: Deranged liver function tests (L.F.Ts) are common in patients treated for Mycobacterium TB, but most patients are able to complete treatment. Routine LFT monitoring in patients without symptoms of hepatotoxicity is unlikely to affect treatment decisions. Recommendation: Deranged liver function tests (L.F.Ts) developed within the first ?months after initiating treatment. Patients taking anti- TB drugs should be followed biochemically during the initial phase of treatment than during the continuous phase and more frequently for those had clinical symptoms of hepatotoxicity or had risk factors.

[Full Text Article]